FDA moves to permanently ban large-scale compounded GLP-1s — what it means for South African patients sourcing from the US

On 30 April 2026, the FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List — the mechanism that allows large-scale outsourcing facilities to compound drugs from raw active pharmaceutical ingredients. The agency’s reasoning: there is no clinical need for compounded versions when FDA-approved products are available. The public comment period closed 29 June 2026.

This follows the removal of semaglutide from the FDA drug shortage list in February 2025 and tirzepatide in December 2024, which already eliminated the primary legal basis for most compounding. The 503B exclusion would close the last remaining pathway for industrial-scale production.

South African patients who have been sourcing compounded GLP-1 products from US-based online pharmacies and telehealth services should be aware that supply from these sources will likely diminish significantly as enforcement tightens. SAHPRA has separately recalled local compounded products (see iDexis recall). The regulatory trajectory in both jurisdictions is toward registered products only.

Sources

1. FDA Federal Register docket 2026-08552
2. Orrick Legal Analysis, May 2026
3. Pharmacy Times, July 2026